Abstract

Long-Term Treatment with Pacritinib on a Compassionate Use Basis in Patients with Advanced Myelofibrosis

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia
John Mascarenhas ... Srdan Verstovsek
Blood | VOL. 138
John Mascarenhas, et. al.John Mascarenhas ... Srdan Verstovsek
05 Nov 2021
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
Marina Kremyanskaya ...
Blood | VOL. 138
Marina Kremyanskaya, et. al.Marina Kremyanskaya ...
05 Nov 2021
Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial
Vikas Gupta ... Moshe Talpaz
Blood | VOL. 138
Vikas Gupta, et. al.Vikas Gupta ... Moshe Talpaz
05 Nov 2021
Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
Abdulraheem Yacoub ... Naval Daver
Blood | VOL. 138
Abdulraheem Yacoub, et. al.Abdulraheem Yacoub ... Naval Daver
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
Samuel Bidot ... Andrew L Feldman
Blood | VOL. 143
Samuel Bidot, et. al.Samuel Bidot ... Andrew L Feldman
27 Jun 2024
GM-CSF brings (good) memories
Damien Reynaud
Blood | VOL. 143
Damien ReynaudDamien Reynaud
27 Jun 2024
Introduction to a review series on oncogenic signaling and immune evasion in hematologic malignancies
Robert Zeiser
Blood | VOL. 143
Robert ZeiserRobert Zeiser
27 Jun 2024
Crespiatico I, Zaghi M, Mastini C, et al. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood. 2024;143(14):1399-1413.
-
Blood | VOL. 143
--
27 Jun 2024
View more papers